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Background: Patients with chronic obstructive pulmonary disease (COPD) present
increased airway resistance, air trapping, pulmonary hyperinflation, and diaphragm
muscle alterations, all of which affect pulmonary mechanics.
Purpose: To evaluate the influence diaphragmatic mobility has on exercise tolerance and
dyspnea in patients with COPD.
Materials and methods: Fifty-four COPD patients with lung hyperinflation were evaluated
to assess pulmonary function, diaphragm mobility, exercise tolerance, and dyspnea
(score). Twenty healthy (age- and body mass index-matched) subjects were evaluated as
controls.
Results: The COPD patients presented lower diaphragmatic mobility than did the controls
(36.27710.96mm vs. 46.3379.46mm). Diaphragmatic mobility presented a linear
correlation with distance covered on the 6-min walk test (6MWT) (r ¼ 0.38; p ¼ 0.005)
and a negative correlation with dyspnea (r ¼ 0.36; p ¼ 0.007). Patients were then
divided into two subgroups based on the degree of diaphragmatic mobility: G1
(p33.99mm) and G2 (X34mm). Those in G1 presented poorer 6MWT performance and
greater dyspnea upon exertion than did those in G2 (distance covered on the 6MWT:
454.767100.67m vs. 521.63770.82m; dyspnea score: 5.2273.06 vs. 3.4872.77). The G1
patients also presented greater residual volume (in liters) and lower maximal voluntaryElsevier Ltd. All rights reserved.
3066 7317; fax: +55 11 3091 7462.
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E. Paulin et al.2114ventilation (in % of predicted values) than did the G2 patients (266.20755.30 vs.
209.74748.49 and 39.00714.94 vs. 58.11720.96).
Conclusion: Diaphragmatic mobility influences dyspnea and exercise tolerance in patients
with COPD.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is character-
ized by progressive obstruction of the airways that is
partially irreversible.1 Patients with COPD commonly pre-
sent increased airflow resistance as well as air trapping and
pulmonary hyperinflation. The hyperinflation alters the
chest wall, putting the respiratory muscles at a mechanical
disadvantage2,3 and thereby increasing respiratory drive and
the sensation of dyspnea.4 In addition, to prevent dyspnea,
COPD patients reduce their activities of daily living, which
leads to social isolation, depression, anxiety, and loss of
physical conditioning,5 as well as having a negative effect on
their quality of life.6
Forced expiratory volume in 1 s (FEV1) is the most
commonly used parameter to establish the severity of
pulmonary impairment and disease progression.1,7,8 How-
ever, some studies have suggested that FEV1 does not
adequately reflect the clinical manifestations of the
disease9,10 and is only weakly associated with the severity
of dyspnea,11,12 health-related quality of life,13 and the
ability to perform activities of daily living.9 In addition, FEV1
does not serve to be a predictor of mortality in COPD
patients.12,14
Pulmonary hyperinflation has been correlated with
adaptation of the diaphragm muscle,15–17 in which the
capacity of the muscle to generate power is maintained but
its displacement is reduced.18 The importance of the
diaphragm in the lung mechanics associated with hyperin-
flation has been the subject of ever-increasing discussion
owing to widespread use of lung volume reduction surgery,19
which increases the range of movement for the diaphragm
muscle.20,21 However, to date, the relationship between
diaphragmatic mobility and functional capacity remains
unknown for COPD patients.
The objective of the present study was to evaluate the
influence of diaphragmatic mobility on exercise tolerance
and dyspnea in patients with COPD.Participants and methods
Subjects
Sixty patients with moderate or severe COPD were evalu-
ated. The COPD diagnosis was based on the criteria
established by the American Thoracic Society.7 All patients
were clinically stable (no respiratory crises or hospitaliza-
tions within the 30 days preceding the study outset) and
were receiving optimized clinical medical treatment.
Patients suffering from other cardiorespiratory diseases or
being oxygen-dependent for any reason were excluded, as
were patients presenting a body mass index (BMI)430kg/m2(classified as obese) or o18.5 kg/m2 (classified as under-
weight). Patients presenting other respiratory diseases
or pleural scars on chest X-rays were also excluded.
Twenty healthy, gender-, age-, and BMI-matched indivi-
duals, none of whom presented any musculoskeletal
diseases or had a history of respiratory disease, were used
as controls. Anthropometric characteristics and pulmonary
function values for COPD patients and healthy subjects are
shown in Table 1. The study was approved by the Ethics
Committee and all participants gave written informed
consent.Pulmonary function tests
Spirometry and whole-body plethysmography were per-
formed using standard equipment (GS II Pulmonary Function
Testing System; Collins, Braintree, MA), including constant
volume body plethysmography, according to American
Thoracic Society standards.7 The parameters measured
were total lung capacity (TLC), functional residual capacity
(FRC), inspiratory capacity (IC), residual volume (RV), FEV1,
forced vital capacity (FVC), and airway resistance. Static
lung volumes are expressed as percentages of the predicted
values calculated.22 In order to measure FEV1, dynamic lung
volumes, and maximal expiratory flows, a volume displace-
ment spirometer (GS II; Collins, Braintree, MA, USA) was
used. Reported spirometry results were based on the best
curve from three maneuvers and are presented as percen-
tage of predicted according to Knudson et al.23 Predicted
values of airway resistance were according to Clausen and
Zarnins.24Diaphragmatic mobility
The subjects were evaluated in order to assess craniocaudal
displacement of the intrahepatic branches of the portal vein
using an ultrasound scanner (Logiq 500, Pro Series;
GE Medical Systems Milwaukee, WI) in mode B.25 The
patients were evaluated in the dorsal decubitus position,
using a 3.5-MHz convex transducer positioned over the
right subcostal region, at an angle of incidence perpendi-
cular to the craniocaudal axis. Initially, the major
left branch of the portal vein was identified in the field
of vision. This branch was identified in all the subjects.
The position of the left portal vein or one of its branches
was marked with a cursor at the end of forced expirations
and inspirations. The craniocaudal displacement was
calculated by measuring the distance, in millimeters,
between these two points. Three measurements were
recorded for each subject, and the greatest value was used
for analysis.
ARTICLE IN PRESS
Table 1 Characteristics of the study COPD patients and healthy subjects.
COPD patients (n ¼ 54) Healthy subjects (n ¼ 20) p
Gender (M:F) 42:12 16:4
Age (years) 62.1578.06 58.3876.52 0.09
BMI (kg/m2) 25.7874.40 26.4672.23 0.25
FEV1 (liters) 1.2470.50 3.2870.53 o0.001
(% of predicted) 49.48718.00 125.91716.68 o0.000
FVC (liters) 2.7370.83 4.1670.74 o0.001
(% of predicted) 82.61721.74 125.09719.32 o0.000
TLC (liters) 7.4071.41 6.4070.92 o0.000
(% of predicted) 140.26715.80 121.1879.84 o0.000
IC (liters) 2.1770.62 3.2670.53 o0.000
(% of predicted) 94.78721.60 140.64726.23 o0.000
RV (liters) 4.5471.18 2.3770.32 o0.000
(% of predicted) 235.54758.46 124.6479.55 o0.000
Data are presented as mean7SD. BMI: body mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; TLC: total
lung capacity; IC: inspiratory capacity; RV: residual volume.
po0.05.
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A six-minute walk test (6MWT) was carried out in a 30m long
corridor. Subjects were instructed to walk from end to end
of the corridor and to cover the greatest distance possible in
the six minutes allotted. Patients who stopped walking
during the test and needed a rest due to dyspnea were
instructed to continue walking as soon as they felt able, but
the timer was not stopped. The subjects received verbal
encouragement once every minute. Heart rate, respiratory
rate, peripheral oxygen saturation, and subjective dyspnea
score (modified Borg scale) were determined before and
after each test.26 Two tests were performed, 1 h apart, and
the greatest distance covered on the 6MWTwas recorded as
the baseline value.27
Dyspnea
As mentioned above, dyspnea was assessed before and after
each 6MWT using the modified Borg scale.26 Scores denote
the intensity of the dyspnea, ranging from 0 (no dyspnea) to
10 (extremely intense dyspnea).
Statistical analysis
Data are expressed as mean7standard deviation. Kolmogorov–
Smirnov and Levene tests were used to analyze the normal-
ity and homogeneity of variance. Correlations between
diaphragmatic mobility and other parameters were assessed
using Spearman’s correlation test. Patients were allocated
to one of two subgroups according to diaphragmatic
mobility, based on the median value: G1 (lower diaphrag-
matic mobility, p33.99mm); and G2 (higher diaphragmatic
mobility, X34mm). The Student’s t-test for paired data
was used to compare the difference of values obtained ineach group and the Mann–Whitney test was used for
unpaired data. The level of statistical significance was set
at po0.05.Results
Out of a total of 60 COPD patients, 6 were excluded for
presenting an unstable clinical status. The mean age of the
patients was 62.1578.06 years, they were predominantly
(77.7%) male, and the mean BMI was 25.7874.4 kg/m2. All
of the patients presented airflow limitation (mean FEV1/
FVC ¼ 59.48714.25%) and pulmonary hyperinflation
(TLC ¼ 140.26715.8% of predicted). Control subjects pre-
sented similar anthropometric characteristics which are
shown, together with the pulmonary function values for
both groups, in Table 1.
The COPD patients presented less diaphragmatic mobility
than did the controls (36.27710.96mm vs. 46.337
9.46mm). The COPD patients also covered shorter distances
in the 6MWT (492.07791.54m vs. 592.38742.62m). Dia-
phragmatic mobility was found to correlate with RV
(r ¼ 0.60; po0.000), IC (r ¼ 0.41; p ¼ 0.002), the RV/
TLC ratio (r ¼ 0.72; po0.000), and the IC/TLC ratio
(r ¼ 0.55; po0.000, Figure 1). Diaphragmatic mobility
also correlated significantly with performance on the
6MWT (r ¼ 0.38; p ¼ 0.005) and dyspnea score (r ¼ 0.36;
p ¼ 0.007).
As can be seen in Table 2, patients in the G1 and G2
subgroups presented similar values of pulmonary hyperin-
flation, which was determined by calculating the percentage
of predicted TLC (143.64717.24% vs. 137.67714.40%).
However, patients in G1 presented greater air trapping
(expressed as percentage of predicted RV) and lower
maximal voluntary ventilation (percentage of predicted)
than did those in G2 (266.20755.30% vs. 209.74748.49%;
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Figure 1 Relationship between IC/TLC and diaphragmatic mobility in COPD patients.
Table 2 Average values of pulmonary function, capacity of exercise and dyspnea in the groups of patients with COPD.
Group with lesser mobility (G1)
(n ¼ 26)
Group with greater mobility (G2)
(n ¼ 28)
MVV (% of predicted) 39.00714.94 58.11720.96
RV (% of predicted) 266.20755.30 209.74748.49
TLC (% of predicted) 143.64717.24 137.67714.40
IC (% of predicted) 86.76721.73 101.07717.77
6MWT 454.767100.67 521.63770.82
Borg initial 1.3671.28 1.2671.39
Borg final 5.2273.06 3.4872.77
Data are presented as mean7SD. MVV: maximal voluntary ventilation; RV: residual volume; TLC: total lung capacity; IC: inspiratory
capacity; 6MWT: 6-min walk test; G1: group with lesser diaphragm mobility; G2: group with greater diaphragm mobility.
po0.05 in comparison with G1.
E. Paulin et al.2116and 39.00714.94% vs. 58.11720.96%, respectively). Pa-
tients in G1 performed more poorly on the 6MWT than did
those in G2 (454.767100.67m vs. 521.63770.82m). Table 2
also shows that dyspnea score at rest was similar in both
groups (1.3671.28 and 1.2671.39, respectively). However,
dyspnea score upon exertion was higher in G1 than in G2
(5.2273.06 vs. 3.4872.77).Discussion
Our data show that reduced diaphragmatic mobility is
associated with a reduction in physical and ventilatory
capacities as well as with an increase in dyspnea upon
exertion in COPD patients. In addition, our results lend
credence to previous findings showing that COPD patients
present reduced diaphragmatic mobility.
The loss of diaphragmatic mobility observed in our study
is similar to that reported in previous studies.16,17,28 There is
evidence that, in COPD patients presenting hyperinflation,
the diaphragm is the muscle most affected, shortening by
40%,29,30 in contrast with the intercostal muscles, which
shorten by only 7%.31 The reduced respiratory muscle
mobility observed in COPD patients might be attributable
to excessive actin–myosin filament overlap,32 sarcomere
remodeling,33 or both. The main cause of the reduction indiaphragmatic mobility is shortening of the apposition zone
resulting from the absence of the piston-like movement of
the diaphragm.34 The reduced diaphragmatic mobility
observed in the present study cannot be attributed to
factors such as pulmonary fibrosis, pleural scarring or other
lung diseases, since patients presenting such conditions
were excluded.
Based on Laplace’s law,35 it is widely accepted that
pulmonary hyperinflation leads to diaphragmatic mechan-
ical disadvantage. In the present study, COPD patients
presented a wide range of diaphragmatic mobility
(20.371.8mm) suggesting that the extent of alterations
in the diaphragm muscle varies even among patients
presenting the same degree of hyperinflation. When
patients were divided into two subgroups according to the
range of diaphragmatic movement (higher and lower
mobility), it was observed that both groups presented the
same degree of pulmonary hyperinflation. Our results
suggest that the reduction in diaphragmatic mobility in
COPD patients occurs mainly due to air trapping and is not
influenced by pulmonary hyperinflation. Clinically, the
reduction in diaphragmatic mobility is related to the volume
of air a patient can exhale, rather than to the volume that
the patient can inhale.
In the present study, the COPD patients who presented
lower diaphragmatic mobility also presented greater air
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ciated with air trapping but not with pulmonary hyperinfla-
tion. The impact of diaphragmatic mobility on functional
capacity of COPD patients is yet to be determined. Our
results show, for the first time, a positive correlation
between exercise tolerance and diaphragmatic mobility.
Interestingly, the patients presenting lower diaphragmatic
mobility also demonstrated lower exercise tolerance, most
likely due to diaphragmatic mechanical disadvantage, which
hampers ventilation,36 as evidenced by their poor perfor-
mance on the 6MWT. Impaired ventilation, possibly resulting
from air trapping, rectifies the diaphragm in COPD patients,2
alters the length/tension ratio of the muscle, and conse-
quently its function, thereby hindering the ventilatory
response, especially during physical exertion.37 These
diaphragmatic alterations might explain the fact that we
identified, within our sample, a group of patients presenting
reduced diaphragmatic mobility, greater air trapping, and
increased dyspnea after submaximal exercise.
Determining FEV1 is essential to diagnosing and quantify-
ing COPD-related ventilatory impairment.1,7,8 However,
FEV1 does not reflect the systemic manifestations of the
disease or functional impairment of the patient. Recent
studies9,10 have questioned the use of FEV1 alone as an
outcome measure for various interventions or as a measure
of disease severity in patients with COPD. Since using FEV1
to assess pulmonary function makes it appear to remain
unchanged over the course of clinical treatment,10 new
methods that are able to measure changes in the functional
status of COPD patients are required. In COPD patients,
pulmonary rehabilitation increases exercise tolerance, im-
proves health-related quality of life, and decreases dyspnea
without altering pulmonary function.38 The results of the
present study suggest that diaphragmatic mobility is a
parameter that could provide information on respiratory
mechanics and functional capacity in COPD patients. In
addition, our data indicate that assessment of diaphrag-
matic mobility would be useful in assessing functional
impairment in a more comprehensive manner than does
airflow limitation.
In the present study, diaphragmatic mobility was assessed
only on the right side, which might represent a methodo-
logical limitation. Nevertheless, there is evidence in the
literature that right and left hemidiaphragms present
similar mobility.28 In addition, diaphragmatic mobility
assessed using ultrasonography to determine portal vein
displacement presents a high degree of concordance with
diaphragmatic mobility assessed using fluoroscopy.25 These
diaphragmatic mobility values obtained in the present study
are similar to those previously outlined in the literature for
COPD patients.16,17,28 The correlations determined in the
present study were not particularly strong, possibly due to
the fact that COPD is a systemic disease. Common
extrapulmonary effects of COPD include skeletal muscle
dysfunction, osteoporosis, weight loss, reduced exercise
tolerance, and psychological disorders.39
In conclusion, loss of diaphragmatic mobility appears to
be a determining factor for decreased exercise tolerance
and increased dyspnea in COPD patients. Determining
diaphragmatic mobility could further the understanding of
limitations in these patients as well as informing decisions
related to therapeutic strategies.Conflict of interest
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